

Johji Kato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3182366/publications.pdf>

Version: 2024-02-01

81
papers

2,798
citations

147801

31
h-index

182427

51
g-index

84
all docs

84
docs citations

84
times ranked

1924
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac Peptidesâ€™ Current Physiology, Pathophysiology, Biochemistry, Molecular Biology, and Clinical Application. <i>Biology</i> , 2022, 11, 330.	2.8	3
2	Development of a novel human adrenomedullin derivative: human serum albumin-conjugated adrenomedullin. <i>Journal of Biochemistry</i> , 2021, 170, 445-451.	1.7	3
3	Plasma adrenomedullin level and year-by-year variability of body mass index in the general population. <i>Peptides</i> , 2021, 142, 170567.	2.4	2
4	Augmented blood pressure variability following continuous infusion of noradrenaline in rats. <i>Journal of Hypertension</i> , 2020, 38, 314-321.	0.5	4
5	Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. <i>Peptides</i> , 2020, 132, 170352.	2.4	10
6	Adrenomedullin: Continuing to explore cardioprotection. <i>Peptides</i> , 2019, 111, 47-54.	2.4	35
7	Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats. <i>European Journal of Pharmacology</i> , 2017, 806, 91-95.	3.5	5
8	β -arrestins negatively control human adrenomedullin type 1-receptor internalization. <i>Biochemical and Biophysical Research Communications</i> , 2017, 487, 438-443.	2.1	2
9	Angiotensin II Stimulation of Cardiac Hypertrophy and Functional Decompensation in Osteoprotegerin-Deficient Mice. <i>Hypertension</i> , 2016, 67, 848-856.	2.7	18
10	Augmented Blood Pressure Variability in Hypertension Induced by Angiotensin II in Rats. <i>American Journal of Hypertension</i> , 2016, 29, 163-169.	2.0	9
11	Plasma levels of natriuretic peptides and development of chronic kidney disease. <i>BMC Nephrology</i> , 2015, 16, 171.	1.8	16
12	Gender-related alterations in plasma adrenomedullin level and its correlation with body weight gain. <i>Endocrine Connections</i> , 2015, 4, 43-49.	1.9	21
13	Bench-to-bedside pharmacology of adrenomedullin. <i>European Journal of Pharmacology</i> , 2015, 764, 140-148.	3.5	64
14	Biological properties of adrenomedullin conjugated with polyethylene glycol. <i>Peptides</i> , 2014, 57, 118-121.	2.4	29
15	Big angiotensin-25: A novel glycosylated angiotensin-related peptide isolated from human urine. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 757-762.	2.1	23
16	Obesity paradox in peripheral vascular disease. <i>Atherosclerosis</i> , 2013, 229, 509-510.	0.8	3
17	Gender difference in relationship between body mass index and development of chronic kidney disease. <i>BMC Research Notes</i> , 2013, 6, 463.	1.4	19
18	Hemodynamic and Hormonal Changes to Dual Reninâ€™Angiotensin System Inhibition in Experimental Hypertension. <i>Hypertension</i> , 2013, 61, 417-424.	2.7	49

#	ARTICLE	IF	CITATIONS
19	Adrenomedullin Peptides. , 2013, , 1361-1368.		0
20	Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system. Hypertension Research, 2012, 35, 234-238.	2.7	21
21	Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity. Journal of the American Society of Hypertension, 2012, 6, 393-398.	2.3	3
22	Effects of proangiotensin-12 infused continuously over 14 days in conscious rats. European Journal of Pharmacology, 2012, 683, 186-189.	3.5	9
23	Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension. Hypertension Research, 2011, 34, 331-335.	2.7	16
24	Shared and separate functions of the RAMP-based adrenomedullin receptors. Peptides, 2011, 32, 1540-1550.	2.4	52
25	One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertension Research, 2010, 33, 320-325.	2.7	27
26	Plasma and tissue levels of proangiotensin-12 and components of the renin-angiotensin system (RAS) following low- or high-salt feeding in rats. Peptides, 2010, 31, 889-892.	2.4	35
27	Association between body mass index and chronic kidney disease: A population-based, cross-sectional study of a Japanese community. Vascular Health and Risk Management, 2009, 5, 315.	2.3	26
28	Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertension Research, 2009, 32, 597-603.	2.7	73
29	Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H1184-H1192.	3.2	66
30	Adrenomedullin treatment reduces intestinal inflammation and maintains epithelial barrier function in mice administered dextran sulphate sodium. Microbiology and Immunology, 2009, 53, 573-581.	1.4	45
31	Increased plasma levels of the mature and intermediate forms of adrenomedullin in obesity. Regulatory Peptides, 2009, 158, 127-131.	1.9	28
32	Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2614-H2618.	3.2	71
33	Experimental Hypertension is Associated with Differential Expression of Angiotensin-(1-12) in Heart of Hypertensive and Normotensive Rats. FASEB Journal, 2008, 22, 1210.20.	0.5	0
34	Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochemical and Biophysical Research Communications, 2006, 350, 1026-1031.	2.1	163
35	Adrenomedullin alleviates not only neointimal formation but also perivascular hyperplasia following arterial injury in rats. European Journal of Pharmacology, 2005, 508, 201-204.	3.5	7
36	Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Cardiovascular Research, 2005, 65, 921-929.	3.8	25

#	ARTICLE	IF	CITATIONS
37	Adrenomedullin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2480-2487.	2.4	143
38	Effect of adrenomedullin administration on acetic acid-induced colitis in rats. <i>Peptides</i> , 2005, 26, 2610-2615.	2.4	42
39	Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. <i>American Journal of Hypertension</i> , 2005, 18, 354-357.	2.0	24
40	Natriuretic Peptides. , 2004, , 287-290.		2
41	Adrenomedullin Administration Immediately After Myocardial Infarction Ameliorates Progression of Heart Failure in Rats. <i>Circulation</i> , 2004, 110, 426-431.	1.6	72
42	Adrenomedullin induces matrix metalloproteinase-2 activity in rat aortic adventitial fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2004, 325, 80-84.	2.1	27
43	Effects of adrenomedullin (AM) on renin-angiotensin-aldosterone (RAA) system and oxidative stress in rats with acute myocardial infarction (MI). <i>American Journal of Hypertension</i> , 2004, 17, S157-S158.	2.0	0
44	Angiotensin II modulates gene expression of adrenomedullin receptor components in rat cardiomyocytes. <i>Life Sciences</i> , 2003, 73, 1629-1635.	4.3	19
45	Glycine-extended adrenomedullin exerts vasodilator effect through amidation in the rat aorta. <i>Regulatory Peptides</i> , 2003, 113, 109-114.	1.9	14
46	Adrenomedullin: a Possible Autocrine or Paracrine Hormone in the Cardiac Ventricles. <i>Hypertension Research</i> , 2003, 26, S113-S119.	2.7	43
47	Beneficial effects of adrenomedullin on left ventricular remodeling after myocardial infarction in rats. <i>Cardiovascular Research</i> , 2002, 56, 373-380.	3.8	36
48	Aldosterone augments adrenomedullin production without stimulating pro-adrenomedullin N-terminal 20 peptide secretion in vascular smooth muscle cells. <i>Journal of Hypertension</i> , 2002, 20, 1209-1214.	0.5	23
49	Plasma Levels of Adrenomedullin and Atrial and Brain Natriuretic Peptides in the General Population: Their Relations to Age and Pulse Pressure.. <i>Hypertension Research</i> , 2002, 25, 887-892.	2.7	79
50	Effects of Endothelin on Adrenomedullin Secretion and Expression of Adrenomedullin Receptors in Rat Cardiomyocytes. <i>Biochemical and Biophysical Research Communications</i> , 2001, 287, 264-269.	2.1	36
51	Interaction between adrenomedullin (AM) and endothelin (ET) in cultured rat cardiomyocytes. <i>American Journal of Hypertension</i> , 2001, 14, A169.	2.0	0
52	Aldosterone (ALD) augments adrenomedullin (AM) production without any effect on proadrenomedullin N-terminal 20 peptide (PAMP) secretion in human vascular smooth muscle cells (VSMC). <i>American Journal of Hypertension</i> , 2001, 14, A154.	2.0	0
53	Roles of protein kinase C and Ca ²⁺ -dependent signaling in angiotensin II-induced adrenomedullin production in rat cardiac myocytes. <i>Journal of Hypertension</i> , 2001, 19, 757-763.	0.5	10
54	Biosynthesis and Secretion of Adrenomedullin and Proadrenomedullin N-Terminal 20 Peptide in a Rat Model of Endotoxin Shock.. <i>Hypertension Research</i> , 2001, 24, 543-549.	2.7	32

#	ARTICLE	IF	CITATIONS
55	Diastolic wall stress and ANG II in cardiac hypertrophy and gene expression induced by volume overload. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H2939-H2946.	3.2	30
56	Enhanced Adrenomedullin Production by Mechanical Stretching in Cultured Rat Cardiomyocytes. Hypertension, 2000, 35, 1210-1214.	2.7	64
57	Differential responses of circulating and tissue adrenomedullin and gene expression to volume overload. Journal of Cardiac Failure, 2000, 6, 120-129.	1.7	30
58	Atypical Aortic Coarctation with Resistant Hypertension Treated with Axilloiliac Artery Bypass.. Hypertension Research, 2000, 23, 247-249.	2.7	4
59	Plasma Adrenomedullin and Natriuretic Peptides in Patients with Essential or Malignant Hypertension.. Hypertension Research, 1999, 22, 61-65.	2.7	74
60	BIOLOGICAL AND CLINICAL ROLES OF ADRENOMEDULLIN IN CIRCULATION CONTROL AND CARDIOVASCULAR DISEASES. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 371-380.	1.9	83
61	Differential hormonal profiles of adrenomedullin and proadrenomedullin nâ€™terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels. Clinical Cardiology, 1999, 22, 113-117.	1.8	28
62	Secretion and clearance of the mature form of adrenomedullin in humans. Life Sciences, 1999, 64, 2505-2509.	4.3	41
63	An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. Cardiovascular Research, 1999, 43, 958-967.	3.8	104
64	Cholesterol Embolism in a Patient with Inflammatory Abdominal Aortic Aneurysm.. Internal Medicine, 1999, 38, 861-864.	0.7	5
65	The Intermediate Form of Glycine-Extended Adrenomedullin Is the Major Circulating Molecular Form in Human Plasma. Biochemical and Biophysical Research Communications, 1998, 244, 551-555.	2.1	147
66	Adrenomedullin: A Possible Autocrine or Paracrine Inhibitor of Hypertrophy of Cardiomyocytes. Hypertension, 1998, 31, 505-510.	2.7	164
67	Effect of chronically infused adrenomedullin in two-kidney, one-clip hypertensive rats. European Journal of Pharmacology, 1997, 333, 187-190.	3.5	51
68	Purification and characterization of PAMP-12 (PAMP[9-20]) in porcine adrenal medulla as a major endogenous biologically active peptide. FEBS Letters, 1997, 414, 105-110.	2.8	27
69	Production of adrenomedullin in human vascular endothelial cells. Life Sciences, 1997, 60, 1763-1769.	4.3	43
70	HYPOTENSIVE EFFECT OF CHRONICALLY INFUSED ADRENOMEDULLIN IN CONSCIOUS WISTAR-KYOTO AND SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 139-142.	1.9	43
71	Changes in Cardiac Adrenomedullin Concentration in Renovascular Hypertensive Rats.. Hypertension Research, 1997, 20, 113-117.	2.7	22
72	Hypotensive Effect of Chronically Infused Adrenomedullin in Conscious Wistar-Kyoto and Spontaneously Hypertensive Rats. International Heart Journal, 1997, 38, 567-567.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Hyperlipidemia Associated with Multiple Myeloma.. Internal Medicine, 1996, 35, 337-340.	0.7	15
74	Extramedullary Plasmacytoma of the Jejunum.. Internal Medicine, 1996, 35, 422-426.	0.7	7
75	Receptors for adrenomedullin in human vascular endothelial cells. European Journal of Pharmacology, 1995, 289, 383-385.	2.6	109
76	Exercise-Induced Secretion of Brain Natriuretic Peptide in Essential Hypertension and Normal Subjects.. Hypertension Research, 1995, 18, 159-166.	2.7	42
77	Suppression of atrial natriuretic peptide (ANP) receptor recovery from homologous down-regulation by 8-bromo-cGMP in endothelial cells. European Journal of Pharmacology, 1992, 225, 113-117.	2.6	7
78	Cardiac content of brain natriuretic peptide in DOCA-salt hypertensive rats. Life Sciences, 1991, 48, 397-402.	4.3	7
79	NATRIURETIC AND HYPOTENSIVE EFFECTS OF BRAIN NATRIURETIC PEPTIDE IN ANAESTHETIZED DOCA-SALT HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 185-190.	1.9	10
80	Atrial natriuretic polypeptide (ANP) in the development of spontaneously hypertensive rats (SHR) and stroke-prone SHR (SHRSP). Biochemical and Biophysical Research Communications, 1987, 143, 316-322.	2.1	31
81	Increase in plasma atrial natriuretic polypeptide (ANP) following sodium load in anesthetized rats. Life Sciences, 1986, 39, 493-497.	4.3	26